to-BBB receives Frost & Sullivan Technology Innovation Award
to-BBB has been awarded the 2012 European CNS Targeted drug delivery Technology Innovation Award by Frost & Sullivan that is based on extensive research carried out by a team of healthcare analysts.
CNS disorders are a major cause of mortality and debilitation. With increasing prevalence of neurodegenerative diseases and incidence of acute conditions like stroke, there is a need to develop effective therapies to tackle diseases with a CNS component. Frost & Sullivan recognizes that despite the growing understanding of CNS related diseases and the extensive efforts gone into developing molecules that target disease pathways, pharmaceutical and biotech companies still face the fundamental challenge of achieving effective delivery to the brain because of the presence of the neuroprotective blood-brain barrier.
In order to address the challenges of CNS targeted delivery, to-BBB has developed a technology platform (G-Technology®) that uniquely combines components that have already been extensively used in humans including a liposome-based drug delivery system and a targeting peptide ligand (glutathione).
The Frost & Sullivan Technology Innovation Award is a recognition of to-BBB’s accomplishments in the CNS Targeted Drug Delivery field. As an independent, third-party, Frost & Sullivan recognizes to-BBB for delivering excellence and best practices in this challenging field.
Other news from the department research and development
